First-Line Encorafenib, Binimetinib, and Cetuximab Combination Provides Clinical Benefit and Manageable Safety in BRAF V600E–Mutated mCRC
BRAF V600E mutations are identified in 8 to 15% of patients with metastatic colorectal cancer and represent a subtype that carries a poor prognosis